Developing novel Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that target cancer by releasing therapeutic agents directly into the nucleus or cytosol, leveraging new biological transport mechanisms. Target users include cancer patients seeking advanced treatment options.